Wyeth, Orchid Reach Deal In Effexor Patent Fight

Law360, New York (April 15, 2011, 1:35 PM EDT) -- Wyeth LLC on Thursday struck a licensing deal with generics maker Orchid Chemicals & Pharmaceuticals Ltd. over Effexor XR, resolving a patent dispute in New Jersey over the blockbuster antidepressant and anti-anxiety drug.

Under the settlement, Orchid agreed not to manufacture venlafaxine HCl extended-release capsules — the active ingredient in the drug — until the expiration of three relevant patents, except as permitted by a confidential licensing agreement.

Wyeth and Orchid submitted the deal to Judge Freda L. Wolfson of the U.S. District Court for the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.